Quantcast
Last updated on April 18, 2014 at 9:00 EDT

Latest Ulcerative colitis Stories

2013-03-19 08:27:35

GLEN ALLEN, Va., March 19, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI), through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Inc., announced today that it has received positive preliminary results from a study investigating the effects of anatabine in an animal model of idiopathic inflammatory bowel disease, Crohn's disease and ulcerative colitis. This study, performed by researchers in the Department of Medicine at the University of Virginia, assessed the effects...

2013-03-07 12:26:58

OSAKA, Japan, March 7, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), the two most common types of inflammatory bowel disease (IBD). If...

2013-01-31 00:20:19

NEW YORK, Jan. 30, 2013 /PRNewswire-iReach/ -- Having struggled with Crohn's Disease since the early 90's, Warren Sulmasy joined the Crohn's and Colitis Foundation of America (CCFA) in January 2013 to help find a cure for those who struggle with the chronic diseases. In the early 90's, Sulmasy's health began to deteriorate over a period of several months. He lost, 50 pounds and was constantly fatigued. He endured rounds of tests and medication from 12 different doctors until he was finally...

2013-01-04 08:22:56

SAN DIEGO, Jan. 4, 2013 /PRNewswire/ -- Receptos, Inc., announced today that its selective sphingosine?1? phosphate 1 receptor (S1P1R) modulator, RPC1063, has been administered to the first patient in a Phase 2 study examining the clinical efficacy and safety of induction therapy in patients with moderately to severely active ulcerative colitis (UC). Leading to the initiation of the RPC01-202 study, called TOUCHSTONE, Receptos successfully filed an Investigational New Drug (IND) Application...

2012-12-13 12:24:26

OAKLAND, Calif., Dec. 13, 2012 /PRNewswire-USNewswire/ -- The Kenneth Rainin Foundation announced today its 2013 Innovator Awards Program for Inflammatory Bowel Disease (IBD). The Program supports "out-of-the-box" innovative research projects that are potentially transformative to the Foundation's efforts to diagnose, treat and/or cure IBD. The Program is open to tenure track professors (or the equivalent) at all levels from any scientific discipline and from any non-profit research...

2012-11-30 12:25:19

ATLANTA, Nov. 30, 2012 /PRNewswire/ -- In recognition of Crohn's and Colitis Awareness Week (December 1-7), UCB, Inc. is directing a national effort to educate the public about Crohn's disease and inspire those living with the condition to speak out about it. The campaign will hinge on real stories from real people succeeding in the face of Crohn's disease, adding clarity to a misunderstood condition while providing a platform for Crohn's patients to engage and draw support from one another....

2012-11-30 12:24:57

OAKLAND, Calif., Nov. 30, 2012 /PRNewswire-USNewswire/ -- The Kenneth Rainin Foundation announced today its next Innovations Symposium, which will be held on Friday, July 12, 2013 at The Four Seasons Hotel Chicago. This unique one-day symposium will bring together preeminent investigators from a variety of disciplines to present their cutting-edge research on the molecular and cellular aspects of inflammatory and stress response pathways presented in the context of Inflammatory...

2012-11-27 04:21:13

LEXINGTON, Mass., Nov. 27, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AVX-470 for the treatment of ulcerative colitis. AVX-470 is an anti-TNF polyclonal antibody and is the first clinical candidate to come from Avaxia's oral antibody platform. The...

2012-11-08 08:33:58

PRINCETON, N.J., Nov. 8, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its program for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the induction treatment of mild-to-moderate pediatric Crohn's disease has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA). Soligenix has also previously received Orphan Drug Designation...

2012-10-31 15:23:47

CAMBRIDGE, Mass., Oct. 31, 2012 /PRNewswire/ -- ViThera Pharmaceuticals, Inc, a developer of novel therapeutics based on engineered probiotic bacteria, announced today the publication of breakthrough data validating its approach for the delivery of elafin in treating gastrointestinal inflammation. The results were published today by the journal Science Translational Medicine and show use of recombinant probiotic and non-pathogenic food-strain bacteria to deliver elafin, a protein designed to...